MNOV (MediciNova) Current Accrued Expense: $1.89 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MNOV MediciNova Inc MNOV
34 GF Score
Price $1.50
! 3 Warning Signs
View Full Analysis

What is MediciNova Current Accrued Expense?

MediciNova MNOV -4.15% 34 Current Accrued Expense is $1.89 Mil as of Jun. 2026. GuruFocus rates MNOV with a GF Score™ of 34/100. The stock has 3 warning signs investors should review.

MediciNova's Current Accrued Expense for the quarter that ended in Jun. 2026 was $1.89 Mil.

MediciNova's quarterly Current Accrued Expense increased from Dec. 2025 ($1.64 Mil) to Mar. 2026 ($1.65 Mil) and increased from Mar. 2026 ($1.65 Mil) to Jun. 2026 ($1.89 Mil).

MediciNova's annual Current Accrued Expense declined from Dec. 2023 ($1.07 Mil) to Dec. 2024 ($0.75 Mil) but then increased from Dec. 2024 ($0.75 Mil) to Dec. 2025 ($1.64 Mil).

MediciNova Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for MediciNova's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MediciNova Current Accrued Expense Chart

MediciNova Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.11 1.50 1.07 0.75 1.64

MediciNova Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.89 1.89 1.64 1.65 1.89
MNOV
34GF Score
MediciNova Inc MNOV
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MediciNova Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $1.89 Mil mean?
MediciNova (MNOV) has a Current Accrued Expense of $1.89 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on MediciNova and its competitors.
Is MediciNova's Current Accrued Expense too high?
MediciNova's current Current Accrued Expense is $1.89 Mil. Overall, MediciNova has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does MediciNova's Current Accrued Expense compare to CRDF and PMVP?
MediciNova's Current Accrued Expense of $1.89 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on MediciNova and its competitors. MediciNova's current Current Accrued Expense is $1.89 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MediciNova stock overvalued right now?
MediciNova (MNOV) has a current Current Accrued Expense of $1.89 Mil. The current Current Accrued Expense is $1.89 Mil. MediciNova's overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For MediciNova (MNOV), the current Current Accrued Expense is $1.89 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MediciNova Business Description

Other Exchanges 4875:Japan
Address 4275 Executive Square, Suite 300, La Jolla, CA, USA, 92037
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.
34GF Score

Get the complete analysis for MNOV

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.50
Price